<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(11)</volume><submitter>Roy S</submitter><pubmed_abstract>Pancreatic cancer (PC) is the fourth-most-deadly cancer in the United States with a 5-year survival rate of only 8%. The majority of patients with locally advanced pancreatic cancer undergo chemotherapy and/or radiation therapy (RT). However, current treatments are inadequate and novel strategies are desperately required. 3-Bromopyruvate (3-BP) is a promising anticancer drug against pancreatic cancer. It exerts potent anticancer effects by inhibiting hexokinase II enzyme (HK2) of the glycolytic pathway in cancer cells while not affecting the normal cells. 3-BP killed 95% of Panc-2 cells at 15 μM concentration and severely inhibited ATP production by disrupting the interaction between HK2 and mitochondrial Voltage Dependent Anion Channel-1 (VDAC1) protein. Electron microscopy data revealed </pubmed_abstract><journal>American journal of cancer research</journal><pagination>4977-4987</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9729896</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model</pubmed_title><pmcid>PMC9729896</pmcid><pubmed_authors>Bhandary B</pubmed_authors><pubmed_authors>Roy S</pubmed_authors><pubmed_authors>Dukic T</pubmed_authors><pubmed_authors>Tu K</pubmed_authors><pubmed_authors>Molitoris J</pubmed_authors><pubmed_authors>Ko Y</pubmed_authors><pubmed_authors>Shukla H</pubmed_authors></additional><is_claimable>false</is_claimable><name>3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model</name><description>Pancreatic cancer (PC) is the fourth-most-deadly cancer in the United States with a 5-year survival rate of only 8%. The majority of patients with locally advanced pancreatic cancer undergo chemotherapy and/or radiation therapy (RT). However, current treatments are inadequate and novel strategies are desperately required. 3-Bromopyruvate (3-BP) is a promising anticancer drug against pancreatic cancer. It exerts potent anticancer effects by inhibiting hexokinase II enzyme (HK2) of the glycolytic pathway in cancer cells while not affecting the normal cells. 3-BP killed 95% of Panc-2 cells at 15 μM concentration and severely inhibited ATP production by disrupting the interaction between HK2 and mitochondrial Voltage Dependent Anion Channel-1 (VDAC1) protein. Electron microscopy data revealed </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-04T22:14:57.963Z</modification><creation>2025-02-18T23:49:25.589Z</creation></dates><accession>S-EPMC9729896</accession><cross_references/></HashMap>